Literature DB >> 2549225

Kinetic sensitivity of a receptor-binding radiopharmaceutical: technetium-99m galactosyl-neoglycoalbumin.

D R Vera1, E S Woodle, R C Stadalnik.   

Abstract

Kinetic sensitivity is the ability of a physiochemical parameter to alter the time-activity curve of a radiotracer. The kinetic sensitivity of liver and blood time-activity data resulting from a single bolus injection of [99mTc]galactosyl-neoglycoalbumin [( Tc]NGA) into healthy pigs was examined. Three parameters, hepatic plasma flow scaled as flow per plasma volume, ligand-receptor affinity, and total receptor concentration, were tested using [Tc]NGA injections of various molar doses and affinities. Simultaneous measurements of plasma volume (iodine-125 human serum albumin dilution), and hepatic plasma flow (indocyanine green extraction) were performed during 12 [Tc]NGA studies. Paired data sets demonstrated differences (P(chi v2) less than 0.01) in liver and blood time-activity curves in response to changes in each of the tested parameters. We conclude that the [Tc]NGA radiopharmacokinetic system is therefore sensitive to hepatic plasma flow, ligand-receptor affinity, and receptor concentration. In vivo demonstration of kinetic sensitivity permits delineation of the physiologic parameters that determine the biodistribution of a radiopharmaceutical. This delineation is a prerequisite to a valid analytic assessment of receptor biochemistry via kinetic modeling.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2549225

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  6 in total

1.  Optimization via specific fluorescence brightness of a receptor-targeted probe for optical imaging and positron emission tomography of sentinel lymph nodes.

Authors:  Zhengtao Qin; David J Hall; Michael A Liss; Carl K Hoh; Christopher J Kane; Anne M Wallace; David R Vera
Journal:  J Biomed Opt       Date:  2013-10       Impact factor: 3.170

2.  γ-Tilmanocept, a New Radiopharmaceutical Tracer for Cancer Sentinel Lymph Nodes, Binds to the Mannose Receptor (CD206).

Authors:  Abul K Azad; Murugesan V S Rajaram; Wendy L Metz; Frederick O Cope; Michael S Blue; David R Vera; Larry S Schlesinger
Journal:  J Immunol       Date:  2015-07-22       Impact factor: 5.422

3.  A receptor-targeted fluorescent radiopharmaceutical for multireporter sentinel lymph node imaging.

Authors:  Derek K Emerson; Karl K Limmer; David J Hall; Sung-Ho Han; William C Eckelman; Christopher J Kane; Anne M Wallace; David R Vera
Journal:  Radiology       Date:  2012-07-02       Impact factor: 11.105

4.  Measurement of functioning hepatocyte mass via [99mTc]galactosyl-neoglycoalbumin.

Authors:  M Kudo; D R Vera; R C Stadalnik; C O Esquivel; W L Trudeau; K Ikekubo; A Todo
Journal:  Dig Dis Sci       Date:  1993-12       Impact factor: 3.199

Review 5.  Concepts for design and analysis of receptor radiopharmaceuticals: The Receptor-Binding Radiotracers series of meetings provided the foundation.

Authors:  Kenneth A Krohn; David R Vera
Journal:  Nucl Med Biol       Date:  2020-03-12       Impact factor: 2.408

6.  Scintigraphic evaluation of functional hepatic mass in patients with advanced breast cancer.

Authors:  I Virgolini; G Kornek; J Höbart; S R Li; M Raolerer; H Bergmann; W Scheithauer; T Pantev; P Angelberger; H Sinzinger
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.